# Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan

> **NCT04492501** · NA · COMPLETED · sponsor: **UNICEF** · enrollment: 600 (actual)

## Conditions studied

- Covid19
- Cytokine Release Syndrome
- Critical Illness
- ARDS

## Interventions

- **PROCEDURE:** Therapeutic Plasma exchange
- **BIOLOGICAL:** Convalescent Plasma
- **DRUG:** Tocilizumab
- **DRUG:** Remdesivir
- **BIOLOGICAL:** Mesenchymal stem cell therapy

## Key facts

- **NCT ID:** NCT04492501
- **Lead sponsor:** UNICEF
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-01
- **Primary completion:** 2020-07-20
- **Final completion:** 2020-07-20
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2020-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492501, "Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04492501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*